• HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
Thursday, January 28, 2021
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
  • HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

New research supports sofosbuvir in combination with other antivirals for COVID-19

Bioengineer by Bioengineer
October 6, 2020
in Health
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Study demonstrates that RNA terminated by Hepatitis C Drug Sofosbuvir is more resistant to SARS-CoV-2 proofreader than RNA terminated by Remdesivir, and supports the use of Sofosbuvir with other antivirals for COVID-19 clinical trials

IMAGE

Credit: Jingyue Ju/Columbia Engineering

New York, NY–October 6, 2020–Columbia Engineering researchers report that Sofosbuvir-terminated RNA is more resistant to the proofreader of SARS-CoV-2, the virus that causes COVID-19, than Remdesivir-terminated RNA. The results of the new study, published today by the Nature Research journal Scientific Reports, support the use of the FDA-approved hepatitis C drug EPCLUSA–Sofosbuvir/Velpatasvir–in combination with other drugs in COVID-19 clinical trials.

The SARS-CoV-2 exonuclease-based proofreader maintains the accuracy of viral RNA genome replication to sustain virulence. Any effective antiviral targeting the SARS-CoV-2 polymerase must therefore display a certain level of resistance to this proofreading activity.

“We found that the RNA terminated by Sofosbuvir resists removal by the exonuclease to a substantially higher extent than RNA terminated by Remdesivir, another drug being used as a COVID-19 therapeutic,” says the team’s lead PI Jingyue Ju, Samuel Ruben-Peter G. Viele Professor of Engineering; professor of Chemical Engineering and Pharmacology; director, Center for Genome Technology & Biomolecular Engineering.

The new study builds upon earlier work the researchers have conducted. Last January, before COVID-19 reached pandemic status, the team posited that EPCLUSA might inhibit SARS-CoV-2, the virus responsible for COVID-19. Their reasoning was based on the analysis of the molecular structures and activities of hepatitis C viral inhibitors and a comparison of hepatitis C virus and coronavirus replication.

In a subsequent study, the researchers demonstrated that the active drug Sofosbuvir triphosphate is incorporated by SARS-CoV and SARS-CoV-2 polymerases, shutting down the polymerase reaction. Other investigators have since demonstrated the ability of Sofosbuvir to inhibit SARS-CoV-2 replication in lung and brain cells; currently, COVID-19 clinical trials with a number of hepatitis C drugs such as EPCLUSA and the combination of Sofosbuvir and Daclatasvir (which is similar to Velpatasvir) are ongoing in several countries.

Ju notes that a recent preprint from UC Berkeley indicates that a combination of Remdesivir and EPCLUSA increases Remdesivir’s efficacy 25-fold in inhibiting SARS-CoV-2, the virus that causes COVID-19: “These results offer a molecular basis supporting the study of EPCLUSA in combination with Remdesivir for COVID-19 clinical trials.”

###

About the Study

The study is titled “Sofosbuvir terminated RNA is more resistant to SARS CoV 2 proofreader than RNA terminated by Remdesivir.”

Authors are: Steffen Jockusch1,4,5, Chuanjuan Tao1,2,5, Xiaoxu Li1,2, Minchen Chien1,2, Shiv Kumar1,2, Irina Morozova1,2, Sergey Kalachikov1,2, James J. Russo1,2 & Jingyue Ju1,2,3

1Center for Genome Technology and Biomolecular Engineering, Columbia University

2Department of Chemical Engineering, Columbia Engineering

3Department of Molecular Pharmacology and Therapeutics, Columbia University

4Department of Chemistry, Columbia University

The study was supported by Columbia University, a grant from the Jack Ma Foundation, a generous gift from the Columbia Engineering Member of the Board of Visitors Dr. Bing Zhao, and Fast Grants.

The authors declare no competing interests.

LINKS:

Paper: http://www.nature.com/articles/s41598-020-73641-9

DOI: 10.1038/s41598-020-73641-9

http://engineering.columbia.edu/

https://engineering.columbia.edu/faculty/jingyue-ju

https://cheme.columbia.edu/

https://medicalxpress.com/news/2020-02-hepatitis-drug-epclusa-potential-inhibit.html

https://pubs.acs.org/doi/10.1021/acs.jproteome.0c00392

https://www.biorxiv.org/content/10.1101/2020.09.18.302398v1

Columbia Engineering

Columbia Engineering, based in New York City, is one of the top engineering schools in the U.S. and one of the oldest in the nation. Also known as The Fu Foundation School of Engineering and Applied Science, the School expands knowledge and advances technology through the pioneering research of its more than 220 faculty, while educating undergraduate and graduate students in a collaborative environment to become leaders informed by a firm foundation in engineering. The School’s faculty are at the center of the University’s cross-disciplinary research, contributing to the Data Science Institute, Earth Institute, Zuckerman Mind Brain Behavior Institute, Precision Medicine Initiative, and the Columbia Nano Initiative. Guided by its strategic vision, “Columbia Engineering for Humanity,” the School aims to translate ideas into innovations that foster a sustainable, healthy, secure, connected, and creative humanity.

Media Contact
Holly Evarts
[email protected]

Original Source

https://www.engineering.columbia.edu/press-release/jingyue-ju-covid-19-sofosbuvir

Related Journal Article

http://dx.doi.org/10.1038/s41598-020-73641-9

Tags: Biomedical/Environmental/Chemical EngineeringGeneticsInfectious/Emerging DiseasesMedicine/Health
Share12Tweet7Share2ShareShareShare1

Related Posts

IMAGE

Scientists publish a blueprint to apply artificial intelligence to extend human longevity

January 27, 2021
IMAGE

Using wearable tech to keep babies, pregnant women healthy

January 27, 2021

Adults with cognitive disabilities more than twice as likely to use e-cigarettes

January 27, 2021

New study points to better diagnostics for cancer

January 27, 2021
Next Post
IMAGE

Two NRL research physicists named 2020 citation laureates 'of nobel class'

IMAGE

Imaging technique could replace tissue biopsies in assessing drug resistance in cancer

Leave a Reply Cancel reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

POPULAR NEWS

  • IMAGE

    The map of nuclear deformation takes the form of a mountain landscape

    54 shares
    Share 22 Tweet 14
  • People living with HIV face premature heart disease and barriers to care

    69 shares
    Share 28 Tweet 17
  • New drug form may help treat osteoporosis, calcium-related disorders

    41 shares
    Share 16 Tweet 10
  • New findings help explain how COVID-19 overpowers the immune system

    35 shares
    Share 14 Tweet 9

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Tags

Chemistry/Physics/Materials SciencesInfectious/Emerging DiseasesGeneticsEcology/EnvironmentcancerTechnology/Engineering/Computer ScienceClimate ChangeMaterialsPublic HealthBiologyMedicine/HealthCell Biology

Recent Posts

  • Scientists publish a blueprint to apply artificial intelligence to extend human longevity
  • In Brazil, many smaller dams disrupt fish more than large hydropower projects
  • New NCAR-Wyoming supercomputer to accelerate scientific discovery
  • Putting bugs on the menu, safely
  • Contact Us

© 2019 Bioengineer.org - Biotechnology news by Science Magazine - Scienmag.

No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

© 2019 Bioengineer.org - Biotechnology news by Science Magazine - Scienmag.

Welcome Back!

Login to your account below

Forgotten Password?

Create New Account!

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In